6 News & Press Releases found
AVM Biotechnology News
-
AVM Biotechnology Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703’s Potential to Reverse Type 1 Diabetes
AVM Biotechnology, LLC, a clinical stage company advancing AVM0703 in the treatment of Non-Hodgkin’s Lymphoma (NHL)/Leukemia, today announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant. This $1.6 ...
-
AVM Biotechnology Expands C-Suite in Anticipation of 2023 Commercialization Efforts
AVM Biotechnology, a clinical stage company developing AVM0703, a small molecule that mobilizes endogenous gamma delta TCR+ and invariant TCR+ bispecific Natural Killer T-like cells, announced the expansion of its senior management with the ...
-
FDA Approves Accelerated Dosing in Non-Hodgkin’s Lymphoma/Leukemia Clinical Trial
AVM Biotechnology, a clinical-stage company, announced today FDA permission to modify its ongoing clinical study, AVM0703-001, entitled “The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma”. The initial protocol, a 3 x 3-based ...
-
AVM Biotechnology Announces Full Enrollment of First Cohort of Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients dosed with AVM0703 at major Cancer Centers in USA
AVM Biotechnology announced today that the first cohort has been fully enrolled in their clinical study (NCT04329728 “The WWRD Study”). All three patients had failed multiple prior therapies, and one had failed two transplants. These ...
-
Dexamethasone reportedly part of President Trump’s Treatment
As part of the standard of care treatment protocol, President Trump received dexamethasone for his COVID-19 disease, highlighting the value of dexamethasone. Dexamethasone has been widely used since its initial approval in 1958 in treating acute ...
-
Seattle AVM Biotechnology announces second IND for AVM0703: clinical trial permitted to treat COVID-19 and Influenza ARDS with its “supercharged” version of dexamethasone
AVM Biotechnology has received FDA permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients. This is AVM’s ...